The La Roche-Posay North American Foundation was established in 2005 to support outstanding candidates with promising projects in the field of clinical, biological or pharmacological research linked to dermatology. This competitive program is open to dermatology residents, fellows, and new practitioners (up to five years) in the United States.
All submitted applications will be evaluated by a scientific committee.
Three Grants: $10,000, $5,000 & $5,000
To be considered, submit 2 copies of your application in English.
- Abstract (1 page), research plan and budget (8 pages maximum)
- Curriculum Vitae of the applicant
- A letter of support from mentor or chief of dermatology All applications must be postmarked by December 31, 2019 to the
La Roche-Posay Laboratoire Dermatologique
10 Hudson Yards
New York, NY 10001
Attention: Tyler Steele
Grants may also be submitted electronically to: email@example.com
With design input from leading dermatologists, excel V+ is the latest generation laser technology for the treatment of vascular and benign pigmented lesions and skin revitalization concerns. By combining two clinically proven wavelengths, the 532 nm LBO and Cutera’s pioneered 1064 nm Nd:YAG, providers can treat more than 20 indications on the face and body, from challenging vascular and pigmentary issues to today’s most common concerns such as rosacea, leg veins, and our signature Laser Genesis procedure. The excel V+ features several new enhancements, including a large 16 mm spot size for 2X faster treatments, 50% more power with the 532 nm wavelength, and two new revenue streams with the Green Genesis and the Dermastat 532 nm treatments. Combined with its solid-state design, no consumable model, intra-pulse autocalibration, and adjustable sapphire contact cooling, the new excel V+ provides the power, precision, and performance to put your practice ahead of the rest. Learn more about excel V+ at www.cutera. com/excelVplus.
EPI Health, LLC Acquires Worldwide Rights to RHOFADE® from Aclaris Therapeutics, Inc.
EPI Health, LLC, a specialty pharmaceutical company committed to delivering innovative prescription therapies to dermatologists, today announced that it has acquired RHOFADE® (oxymetazoline hydrochloride) cream, 1% (RHOFADE) and related intellectual property assets from Aclaris Therapeutics, Inc. (Nasdaq: ACRS). RHOFADE (oxymetazoline hydrochloride) cream, 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.
The National Rosacea Society (NRS) estimates that approximately 16 million Americans are affected by rosacea. Persistent facial redness (erythema) is cited as the most common sign of rosacea and may resemble a flushing or sunburn that does not go away. Typical triggers include sun exposure, stress, weather, food, and exercise.